Targeted therapy for metastatic renal cell carcinoma.
Targeted therapy for metastatic renal cell carcinoma.
复制标题
DOI：
10.1038/sj.bjc.6602978
复制
发表时间：
2006-03-13
影响因子：
8.8
通讯作者：
中科院分区：
文献类型：
--
作者：
Metastatic renal cell carcinoma (RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide response in a minority of patients. We reviewed RCC biology and explored the ways in which this understanding led to development of novel, effective targeted therapies. Small molecule tyrosine kinase inhibitors, monoclonal antibodies and novel agents are all being studied, and phase II studies show promising activity of sunitinib, sorafenib and bevacizumab. The results of phase III studies will determine the role of these agents in metastatic RCC.
登录
查看更多内容
影响因子：
56.9
作者：
Kamura, T;Koepp, DM;Conway, JW
通讯作者：
Conway, JW
影响因子：
64.8
作者：
Hon, WC;Wilson, MI;Jones, EY
通讯作者：
Jones, EY
影响因子：
45.3
作者：
Atkins, MB;Hidalgo, M;Sherman, ML
通讯作者：
Sherman, ML
影响因子：
45.3
作者：
Motzer, RJ;Michaelson, MD;Rini, BI
通讯作者：
Rini, BI
DOI：
10.1073/pnas.91.21.9700
发表时间：
1994-10-11
影响因子：
11.1
作者：
HERMAN, JG;LATIF, F;BAYLIN, SB
通讯作者：
BAYLIN, SB